Razavi Yasaman, Keyhanfar Fariborz, Shabani Ronak, Haghparast Abbas, Mehdizadeh Mehdi
Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.
Department of Pharmacology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Iran J Pharm Res. 2021 Fall;20(4):152-164. doi: 10.22037/ijpr.2021.114918.15106.
As a strong and addictive psychostimulant, methamphetamine (METH) is often misused worldwide. Although relapse is the greatest challenge to the effective treatment of drug dependency, now, for METH addiction, there is not available accepted pharmacotherapy. To characterize a probable new target in this indication, a biological system comprised of endocannabinoids, known as the endocannabinoid system (ECS), has been advised. As a non-psychotomimetic Phytocannabinoid in , cannabidiol (CBD) has been used in preclinical and clinical studies for treating neuropsychiatric disorders. In this review article, we focus on the effects of CBD in the treatment of addiction in a preclinical investigation concerning the pharmaceutic effectiveness and the underlying mechanisms of action on drug abuse specially METH. Growing evidence shows that CBD is a potential therapeutic agent in reducing drug reward, as evaluated in conditioned place preference (CPP), brain-stimulation reward paradigms, and self- administration. Furthermore, CBD plays an effective role in decreasing relapse in animal research. Through multiple-mechanisms, there is a belief that CBD modulates brain dopamine responding to METH, resulting in a reduction of METH-seeking behaviors. As our studies indicate, CBD can decrease METH addiction-associated problems, for example, symptoms of withdrawal and craving. It is needed for conducting more preclinical investigations and upcoming clinical trials to entirely assess the CBD capability as interference for METH addiction.
作为一种强效且易成瘾的精神兴奋剂，甲基苯丙胺（METH）在全球范围内常被滥用。尽管复发是药物依赖有效治疗面临的最大挑战，但目前对于甲基苯丙胺成瘾，尚无被广泛认可的药物疗法。为了确定这一适应症中可能的新靶点，有人提出了一种由内源性大麻素组成的生物系统，即内源性大麻素系统（ECS）。大麻二酚（CBD）作为一种非致幻性植物大麻素，已被用于治疗神经精神疾病的临床前和临床研究。在这篇综述文章中，我们聚焦于在一项临床前研究中CBD对成瘾治疗的影响，该研究涉及药物疗效以及其对药物滥用尤其是甲基苯丙胺作用的潜在机制。越来越多的证据表明，如在条件性位置偏爱（CPP）、脑刺激奖赏范式和自我给药实验中所评估的那样，CBD是一种减少药物奖赏的潜在治疗剂。此外，在动物研究中，CBD在减少复发方面发挥着有效作用。人们认为，CBD通过多种机制调节大脑对甲基苯丙胺的多巴胺反应，从而减少对甲基苯丙胺的寻求行为。正如我们的研究所表明的，CBD可以减少与甲基苯丙胺成瘾相关的问题，例如戒断症状和渴望。需要进行更多的临床前研究和即将开展的临床试验，以全面评估CBD作为甲基苯丙胺成瘾干预措施的能力。
